NeoGenomics, Inc. (NEO) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
42/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinNEO / S&P 96.63% / 15.20% |
LoseNEO / S&P 11.19% / 15.00% |
LoseNEO / S&P NEO unavailable / 50.40% |
| 2026-Q10/3 |
LoseNEO / S&P -36.90% / -4.33% |
LoseNEO / S&P 10.95% / 11.30% |
LoseNEO / S&P NEO unavailable / 27.70% |
| 2025-Q42/3 |
WinNEO / S&P 52.33% / 2.65% |
WinNEO / S&P 10.11% / 9.00% |
LoseNEO / S&P NEO unavailable / 13.40% |
| 2025-Q31/3 |
LoseNEO / S&P 5.61% / 8.12% |
WinNEO / S&P 10.10% / 4.61% |
LoseNEO / S&P NEO unavailable / 13.45% |
| 2025-Q21/3 |
LoseNEO / S&P -22.97% / 10.94% |
WinNEO / S&P 9.70% / 4.83% |
LoseNEO / S&P NEO unavailable / 10.63% |
| 2025-Q11/3 |
LoseNEO / S&P -42.42% / -4.27% |
WinNEO / S&P 10.10% / 4.98% |
LoseNEO / S&P NEO unavailable / 10.57% |
| 2024-Q42/3 |
WinNEO / S&P 11.73% / 2.41% |
WinNEO / S&P 11.65% / 5.25% |
LoseNEO / S&P NEO unavailable / 6.15% |
| 2024-Q32/3 |
WinNEO / S&P 6.34% / 5.89% |
WinNEO / S&P 12.06% / 5.89% |
LoseNEO / S&P NEO unavailable / 6.11% |
| 2024-Q21/3 |
LoseNEO / S&P -11.77% / 4.28% |
WinNEO / S&P 13.89% / 5.38% |
LoseNEO / S&P NEO unavailable / 5.12% |
| 2024-Q11/3 |
LoseNEO / S&P -2.84% / 10.56% |
WinNEO / S&P 15.27% / 5.71% |
LoseNEO / S&P NEO unavailable / 5.59% |
| 2023-Q42/3 |
WinNEO / S&P 31.54% / 11.69% |
WinNEO / S&P 16.07% / 6.81% |
LoseNEO / S&P NEO unavailable / 7.78% |
| 2023-Q31/3 |
LoseNEO / S&P -23.46% / -3.27% |
WinNEO / S&P 15.71% / 7.52% |
LoseNEO / S&P NEO unavailable / -5.03% |
| 2023-Q21/3 |
LoseNEO / S&P -7.70% / 8.74% |
WinNEO / S&P 12.73% / 9.50% |
LoseNEO / S&P NEO unavailable / -8.57% |
| 2023-Q11/3 |
WinNEO / S&P 88.42% / 7.50% |
LoseNEO / S&P 9.02% / 10.77% |
LoseNEO / S&P NEO unavailable / -15.69% |
| 2022-Q40/3 |
LoseNEO / S&P 7.32% / 7.56% |
LoseNEO / S&P 5.24% / 11.88% |
LoseNEO / S&P NEO unavailable / -17.99% |
| 2022-Q31/3 |
WinNEO / S&P 5.64% / -4.88% |
LoseNEO / S&P 2.51% / 13.47% |
LoseNEO / S&P NEO unavailable / -1.41% |
| 2022-Q20/3 |
LoseNEO / S&P -32.92% / -16.10% |
LoseNEO / S&P 0.13% / 13.71% |
LoseNEO / S&P NEO unavailable / 11.04% |
| 2022-Q10/3 |
LoseNEO / S&P -64.39% / -4.60% |
LoseNEO / S&P 7.05% / 15.97% |
LoseNEO / S&P NEO unavailable / 42.23% |
| 2021-Q40/3 |
LoseNEO / S&P -29.27% / 11.03% |
LoseNEO / S&P 8.97% / 15.00% |
LoseNEO / S&P NEO unavailable / 96.40% |
| 2021-Q32/3 |
WinNEO / S&P 6.80% / 0.58% |
WinNEO / S&P 13.94% / 10.77% |
LoseNEO / S&P NEO unavailable / 69.42% |
| 2021-Q21/3 |
LoseNEO / S&P -6.34% / 8.55% |
WinNEO / S&P 20.80% / 6.58% |
LoseNEO / S&P NEO unavailable / 51.81% |
| 2021-Q11/3 |
LoseNEO / S&P -10.42% / 6.17% |
WinNEO / S&P 8.27% / -1.06% |
LoseNEO / S&P NEO unavailable / 7.39% |
| 2020-Q42/3 |
WinNEO / S&P 45.95% / 12.15% |
WinNEO / S&P 8.71% / -3.72% |
LoseNEO / S&P NEO unavailable / -33.42% |
| 2020-Q32/3 |
WinNEO / S&P 19.08% / 8.93% |
WinNEO / S&P 12.39% / -2.04% |
LoseNEO / S&P NEO unavailable / -27.10% |
| 2020-Q21/3 |
LoseNEO / S&P 12.21% / 20.54% |
WinNEO / S&P 17.99% / -0.46% |
LoseNEO / S&P NEO unavailable / -27.11% |
| 2020-Q12/3 |
WinNEO / S&P -5.61% / -19.60% |
WinNEO / S&P 35.74% / 3.47% |
LoseNEO / S&P NEO unavailable / -14.75% |
| 2019-Q42/3 |
WinNEO / S&P 52.98% / 9.07% |
WinNEO / S&P 47.73% / 5.36% |
LoseNEO / S&P NEO unavailable / 2.99% |
| 2019-Q31/3 |
LoseNEO / S&P -12.85% / 1.70% |
WinNEO / S&P 44.61% / 5.02% |
LoseNEO / S&P NEO unavailable / 0.21% |
| 2019-Q22/3 |
WinNEO / S&P 7.23% / 4.30% |
WinNEO / S&P 36.20% / 6.64% |
LoseNEO / S&P NEO unavailable / 8.65% |
| 2019-Q12/3 |
WinNEO / S&P 62.25% / 13.65% |
WinNEO / S&P 25.44% / 8.12% |
LoseNEO / S&P NEO unavailable / 14.29% |
| 2018-Q41/3 |
LoseNEO / S&P -17.85% / -13.52% |
WinNEO / S&P 15.19% / 9.05% |
LoseNEO / S&P NEO unavailable / 18.23% |
| 2018-Q31/3 |
WinNEO / S&P 17.09% / 7.71% |
LoseNEO / S&P NEO unavailable / 10.21% |
LoseNEO / S&P NEO unavailable / 19.06% |
| 2018-Q21/3 |
WinNEO / S&P 60.66% / 3.43% |
LoseNEO / S&P NEO unavailable / 9.03% |
LoseNEO / S&P NEO unavailable / 14.46% |
| 2018-Q10/3 |
LoseNEO / S&P -7.90% / -0.76% |
LoseNEO / S&P NEO unavailable / 7.68% |
LoseNEO / S&P NEO unavailable / 12.46% |
| 2017-Q40/3 |
LoseNEO / S&P -20.40% / 6.64% |
LoseNEO / S&P NEO unavailable / 7.03% |
LoseNEO / S&P NEO unavailable / 13.82% |
| 2017-Q31/3 |
WinNEO / S&P 24.22% / 4.48% |
LoseNEO / S&P NEO unavailable / 5.68% |
LoseNEO / S&P NEO unavailable / 17.57% |
| 2017-Q21/3 |
WinNEO / S&P 13.56% / 3.09% |
LoseNEO / S&P NEO unavailable / 4.83% |
LoseNEO / S&P NEO unavailable / 17.74% |
| 2017-Q10/3 |
LoseNEO / S&P -7.93% / 6.07% |
LoseNEO / S&P NEO unavailable / 3.67% |
LoseNEO / S&P NEO unavailable / 13.32% |
| 2016-Q41/3 |
WinNEO / S&P 4.26% / 3.82% |
LoseNEO / S&P NEO unavailable / 2.09% |
LoseNEO / S&P NEO unavailable / 7.05% |
| 2016-Q30/3 |
LoseNEO / S&P 2.24% / 3.85% |
LoseNEO / S&P NEO unavailable / 0.20% |
LoseNEO / S&P -2400.00% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | NEO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 112.30% | 20.78% |
| Annualized return | 112.30% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | NEO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -62.91% | 83.14% |
| Annualized return | -17.99% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | NEO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 134.47% | 319.30% |
| Annualized return | 8.89% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |